Special Issue

Pharmacological Treatment of Hearing Loss

Message from the Guest Editors

Hearing loss is recognized as a serious health problem, especially in the generic population, but also in the industrialized environment, where the level of noise can increase hearing loss among children, young, and middle-aged people. To date, there is no widely used pharmacological treatment officially approved by the FDA (Food and Drug Administration) or EMA (European Medical Agency). The prevention of death of hearing cells can be incredibly challenging. For people with severe to profound hearing loss, cochlear implants are the only option, while for less severe cases, hearing aids are possible. As a result, questions about possible, effective, and safe pharmacological treatment are still open. This Special Issue of 'Pharmacological Treatment of Hearing Loss' aims to focus on major developments related to the pharmacological and biological treatment of hearing loss and possible mechanisms (pharmacological approaches of prevention of hearing loss caused by exposure to moderate levels of noise in the workplace (e.g., machinery), recreational environments (e.g., loud music, motorcycles), drug, agerelated hearing loss, ototoxic agents, and many other factors.

Guest Editors

Dr. Magdalena B. Skarżyńska Institute of Sensory Organs, 05-830 Kajetany, Poland

Prof. Dr. Piotr Henryk Skarżyński

Teleaudiology and Screening Department, World Hearing Center, The Institute of Physiology and Pathology of Hearing, 02-042 Warsaw, Poland

Deadline for manuscript submissions

closed (31 October 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/148193

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

